Drug rebates for statutory health insurances – AMNOG generates almost half of all savings
About the author
Dipl.-Kauffrau Heike Kielhorn-Schönermark
Founder and Managing Director
Founder and Managing Director
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18
Fax: +49 511 64 68 14 18
The expenditures for SHI insured persons amounted to 38 billion euro in 2017 and are thus 4% higher than the previous year’s level. However, this cannot be traced back to savings from manufacturers’ rebates because they increased by 16% to a total amount of 3.28 billion euro in comparison to 2016. With 1.57 billion euro almost half of all savings (48%) are rebates from reimbursement. For the first time, this part overtakes the savings from mandatory rebates that rose by 2% to 1.26 billion euro. Furthermore, the savings of the 10% generic drugs rebate increased slightly to 144 million euro in comparison to the previous year. Solely for additional discounts from price moratoriums a moderate decrease to 307 million euro took place. Moreover, the SHIs gain further savings from rebate contracts. Savings of approximately 3.9 billion euro are expected for 2017. Thus, the total savings of SHIs amount to 7.2 billion Euro.The market report shows that the savings resulted from AMNOG are enormous, although the goal of annual savings of 2.2 billion euro has still not been achieved.
As the leading strategy consultancy for health care in Germany SKC keeps you up to date with news of the AMNOG process. Do you have any questions concerning AMNOG, SHIs or other health care issues? Please feel free to contact us.
BY Heike Kielhorn-Schönermark, MBA, managing director and Karolin Priese, MBA
Sources:
Bundesministerium für Gesundheit: Arzneimittelmarktneuordnungsgesetz (AMNOG) (German only)
Deutsches Ärzteblatt: AMNOG bringt deutlich mehr Einsparungen (German only)
IQVIA: German Market Report